¼¼°èÀÇ ·¦¿Â¾îĨ ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м® º¸°í¼ : Á¦Ç° ¹× ¼ºñ½ºº°, ±â¼úº°, ¿ëµµº°, ÃÖÁ¾ ¿ëµµº°, Áö¿ªº°, ºÎ¹® ¿¹Ãø(2025-2030³â)
Lab-on-a-Chip Market Size, Share & Trends Analysis Report By Product & Service, By Technology, By Application, By End Use, By Region, And Segment Forecasts, 2025 - 2030
»óǰÄÚµå
:
1701238
¸®¼Ä¡»ç
:
Grand View Research, Inc.
¹ßÇàÀÏ
:
2025³â 03¿ù
ÆäÀÌÁö Á¤º¸
:
¿µ¹® 100 Pages
¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
·¦¿Â¾îĨ ½ÃÀåÀÇ ¼ºÀå°ú µ¿Çâ :
Grand View Research, Inc.ÀÇ ÃֽŠº¸°í¼¿¡ µû¸£¸é, ¼¼°è ·¦¿Â¾îĨ ½ÃÀå ±Ô¸ð´Â 2030³â±îÁö 114¾ï 5,000¸¸ ´Þ·¯¿¡ ´ÞÇϰí, 2025-2030³â 9.76%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)À» º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.
ÀÌ ½ÃÀåÀº ÇコÄɾî R&D¿¡ ´ëÇÑ ÅõÀÚ Áõ°¡, Áø´Ü¿¡ ´ëÇÑ AIÀÇ ÅëÇÕ, °³ÀÎ ¸ÂÃãÇü ÀÇ·á ¹× ºÐ»êÇü °Ë»ç¸¦ Áö¿øÇÏ´Â Á¤ºÎÀÇ ÀÌ´Ï¼ÅÆ¼ºê¿¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù.
·¦¿Â¾îĨ ½ÃÀåÀº Áø´Ü ÇÁ·Î¼¼½ºÀÇ Á¤È®¼º°ú È¿À²¼ºÀ» Çâ»ó½ÃŰ´Â ¸¶ÀÌÅ©·ÎÇ÷çÀ̵ñ½º ±â¼úÀÇ ¹ßÀüÀ¸·Î ÀÎÇØ Å©°Ô ¼ºÀåÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ·¦¿ÂĨ µð¹ÙÀ̽º°¡ ÀÓ»ó ½ÇÇè½Ç°ú ¿¬±¸½Ç¿¡ ÅëÇÕµÇ¸é¼ ¿öÅ©Ç÷ο찡 °£¼ÒÈµÇ¾î º¹ÀâÇÑ ºÐ¼®¿¡ ¼Ò¿äµÇ´Â ½Ã°£ÀÌ ´õ¿í ´ÜÃàµÇ°í ÀÖ½À´Ï´Ù. Á¦¾à ¹× »ý¸í°øÇÐ »ê¾÷¿¡¼ ³ôÀº 󸮷® ½ºÅ©¸®´×¿¡ ´ëÇÑ ¼ö¿ä´Â ·¦¿ÂĨ ±â¼úÀÇ Àû¿ëÀ» È®´ëÇÏ¿© º¸´Ù ½Å¼ÓÇÑ ½Å¾à °³¹ß ¹× ¸ÂÃã Ä¡·á Á¢±Ù¹ýÀ» °¡´ÉÇÏ°Ô Çϰí ÀÖ½À´Ï´Ù.
¶ÇÇÑ, ¿ø°Ý ÀÇ·á ¹× ¿ø°Ý ȯÀÚ ¸ð´ÏÅ͸µÀÇ Ã¤ÅÃÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ÈÞ´ë¿ë Áø´Ü ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖÀ¸¸ç, ·¦¿ÂĨÀº ºÐ»êÇü ÇコÄÉ¾î ½Ã½ºÅÛÀÇ Áß¿äÇÑ ±¸¼º ¿ä¼Ò·Î ÀÚ¸® Àâ°í ÀÖ½À´Ï´Ù. ±â¼úÀÇ ¹ßÀüÀ¸·Î ·¦¿ÂĨ Á¦Á¶ÀÇ È®À强ÀÌ Çâ»óµÇ¾î ÀÌ·¯ÇÑ µð¹ÙÀ̽º°¡ ´õ¿í Ä£¼÷ÇØÁö°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÇコÄɾî Çõ½Å¿¡ ´ëÇÑ Á¤ºÎ Àڱݰú ¹Î°£ ÅõÀÚ Áõ°¡·Î ÀÎÇØ ·¦¿ÂĨ ±â¼úÀÇ ¿¬±¸¿Í »ó¿ëȰ¡ ´õ¿í °¡¼Óȵǰí ÀÖ½À´Ï´Ù.
½ÃÀåÀÇ ÁÖ¿ä ¾÷üµéÀº ÷´Ü ¸¶ÀÌÅ©·ÎÇ÷çÀ̵ñ½º°øÇÐ, AI ±â¹Ý ºÐ¼®, »ýü ¸ð¹æ ½Ã½ºÅÛÀ» ÅëÇÕÇÏ¿© ·¦¿ÂĨ ±â¼úÀÇ È¿°ú¿Í ½Å·Ú¼ºÀ» ³ôÀ̱â À§ÇØ ´Ù¾çÇÑ Àü·«À» äÅÃÇϰí ÀÖ½À´Ï´Ù. °¢ ȸ»ç´Â °³ÀÎ ¸ÂÃãÇü ÀÇ·á ¹× ºÐ»êÇü ÇコÄɾ ´ëÇÑ ¼ö¿ä Áõ°¡¿¡ ´ëÀÀÇϱâ À§ÇØ ¾à¹° °Ë»ç Á¤È®µµ Çâ»ó, Àå±â ¿ÂĨ ¸ðµ¨, ÇöÀå Áø´Ü¿¡ ÁýÁßÇϰí ÀÖÀ¸¸ç, 2024³â 9¿ù ¿¡¹Ä·¹ÀÌÆ®´Â ¾à¹° Èí¼ö¸¦ ÃÖ¼ÒÈÇÏ°í »ý¹°ÇÐÀû ¸ðµ¨¸µÀ» °ÈÇϱâ À§ÇØ °í¾ÈµÈ Chip-R1 Rigid ChipÀÇ Ãâ½Ã¸¦ ¹ßÇ¥Çß½À´Ï´Ù. ÀÌ Çõ½ÅÀº in vitro ½ÃÇè Áß ÈÇÕ¹° ¼Õ½Ç ¹®Á¦¸¦ ÇØ°áÇÏ°í ¾àµ¿ÇÐ ¹× µ¶¼º Æò°¡ÀÇ Á¤È®¼ºÀ» Çâ»ó½Ãų ¼ö ÀÖ½À´Ï´Ù.
·¦¿Â¾îĨ ½ÃÀå º¸°í¼ ÇÏÀ̶óÀÌÆ®
- Á¦Ç° ¹× ¼ºñ½ºº°·Î´Â ½Ã¾à ¹× ¼Ò¸ðǰÀÌ Áø´Ü ÀýÂ÷¿¡¼ Áß¿äÇÑ ¿ªÇÒÀ» ÇÏ°í °í°¨µµ ¹× ³ôÀº Á¤È®µµ¸¦ º¸ÀåÇϱ⠶§¹®¿¡ ½ÃÀåÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù. ÀÏȸ¿ë īƮ¸®Áö ¹× ¸¶ÀÌÅ©·ÎÇ÷çÀ̵ñ½º ½Ã¾à¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡´Â ½ÃÀå ¼ºÀåÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù.
- ±â¼úº°·Î´Â ¸¶ÀÌÅ©·ÎÇ÷çÀ̵ñ½º ±â¼úÀÌ 2024³â °¡Àå Å« ¸ÅÃâ Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. ÀÌ´Â ¸¶ÀÌÅ©·Î ½ºÄÉÀÏ¿¡¼ Á¤¹ÐÇÑ À¯Ã¼ Ãë±ÞÀÌ °¡´ÉÇÏ¿© Áø´ÜÀÇ Á¤È®¼º°ú È¿À²¼ºÀ» Çâ»ó½Ãų ¼ö Àֱ⠶§¹®ÀÔ´Ï´Ù.
- ¿ëµµº°·Î´Â ½Å¼ÓÇÏ°í ºñ¿ë È¿À²ÀûÀ̸ç Á¤È®ÇÑ Áúº´ °ËÃâ¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ´Â ÀÓ»ó Áø´ÜÀÌ 2024³â °¡Àå Å« ¸ÅÃâ Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. °¨¿°¼º Áúȯ °Ë»ç, ¾Ï °ËÁø, À¯ÀüÀÚ °Ë»ç µî¿¡ ·¦¿ÂĨÀÌ ³Î¸® »ç¿ëµÇ°í ÀÖ´Â °ÍÀÌ ½ÃÀå ¼ºÀåÀ» °ßÀÎÇϰí ÀÖ½À´Ï´Ù.
- ÃÖÁ¾ ¿ëµµº°·Î´Â º´¿ø ¹× Áø´Ü¼¾ÅͰ¡ Áø´Ü ¸ñÀûÀ¸·Î ·¦¿ÂĨ ±â¼úÀ» ±¤¹üÀ§ÇÏ°Ô »ç¿ëÇÔ¿¡ µû¶ó 2024³â °¡Àå Å« ¸ÅÃâ Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.
- Áö¿ªº°·Î´Â ºÏ¹Ì°¡ 2024³â ½ÃÀåÀ» ÁÖµµÇß°í,, ´Ù¼öÀÇ ÁÖ¿ä Á¦¾à ¹× »ý¸í°øÇÐ ±â¾÷ÀÌ Á¸ÀçÇϰí ÷´Ü Áø´Ü ¹× °Ë»ç ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÁÖµµÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.
¸ñÂ÷
Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§
Á¦2Àå ÁÖ¿ä ¿ä¾à
Á¦3Àå ·¦¿Â¾îĨ ½ÃÀå º¯¼ö, µ¿Çâ, ¹üÀ§
- ½ÃÀå °èÅë Àü¸Á
- »óÀ§ ½ÃÀå Àü¸Á
- °ü·Ã/ºÎ¼ö ½ÃÀå Àü¸Á
- ½ÃÀå ¿ªÇÐ
- ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ ºÐ¼®
- ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ ºÐ¼®
- ¾÷°è ºÐ¼® Åø
- PorterÀÇ Five Forces ºÐ¼®
- PESTEL ºÐ¼®
- COVID-19ÀÇ ¿µÇ⠺м®
- ·¦¿Â¾îĨ ½ÃÀå AIÅëÇÕ
Á¦4Àå ·¦¿Â¾îĨ ½ÃÀå : Á¦Ç° ¹× ¼ºñ½ºº° ÃßÁ¤¡¤µ¿Ç⠺м®
- ºÎ¹® ´ë½Ãº¸µå
- ¼¼°è ½ÃÀå º¯µ¿ ºÐ¼®
- ¼¼°è ½ÃÀå ±Ô¸ð¿Í µ¿Ç⠺м®, 2018-2030³â
- ½Ã¾à ¹× ¼Ò¸ðǰ
- ±â±â
- ¼ÒÇÁÆ®¿þ¾î ¹× ¼ºñ½º
Á¦5Àå ·¦¿Â¾îĨ ½ÃÀå : ±â¼úº° ÃßÁ¤¡¤µ¿Ç⠺м®
- ºÎ¹® ´ë½Ãº¸µå
- ¼¼°è ½ÃÀå º¯µ¿ ºÐ¼®
- ¼¼°è ½ÃÀå ±Ô¸ð¿Í µ¿Ç⠺м®, 2018-2030³â
- ¸¶ÀÌÅ©·ÎÇ÷çÀ̵ñ½º ±â¼ú
- ±¤ÇÐ ±â¼ú
- Àü±âÈÇÐ ±â¼ú
- ±âŸ
Á¦6Àå ·¦¿Â¾îĨ ½ÃÀå : ¿ëµµº° ÃßÁ¤¡¤µ¿Ç⠺м®
- ºÎ¹® ´ë½Ãº¸µå
- ¼¼°è ½ÃÀå º¯µ¿ ºÐ¼®
- ¼¼°è ½ÃÀå ±Ô¸ð¿Í µ¿Ç⠺м®, 2018-2030³â
- Drug Discovery & Development
- ÀÓ»ó Áø´Ü
- ±âŸ
Á¦7Àå ·¦¿Â¾îĨ ½ÃÀå : ÃÖÁ¾ ¿ëµµº° ÃßÁ¤¡¤µ¿Ç⠺м®
- ºÎ¹® ´ë½Ãº¸µå
- ¼¼°è ½ÃÀå º¯µ¿ ºÐ¼®
- ¼¼°è ½ÃÀå ±Ô¸ð¿Í µ¿Ç⠺м®, 2018-2030³â
- º´¿ø ¹× Áø´Ü¼¾ÅÍ
- Á¦¾à ±â¾÷ ¹× ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ±â¾÷
- ±âŸ
Á¦8Àå ·¦¿Â¾îĨ ½ÃÀå : Áö¿ªº° ÃßÁ¤¡¤µ¿Ç⠺м®
- Áö¿ªº° ½ÃÀå Á¡À¯À² ºÐ¼®, 2024³â ¹× 2030³â
- Áö¿ª ½ÃÀå ´ë½Ãº¸µå
- ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø ¹× µ¿Ç⠺м®, 2018-2030³â
- ºÏ¹Ì
- À¯·´
- ¿µ±¹
- µ¶ÀÏ
- ÇÁ¶û½º
- ÀÌÅ»¸®¾Æ
- ½ºÆäÀÎ
- µ§¸¶Å©
- ½º¿þµ§
- ³ë¸£¿þÀÌ
- ¾Æ½Ã¾ÆÅÂÆò¾ç
- ÀϺ»
- Áß±¹
- Àεµ
- È£ÁÖ
- ű¹
- Çѱ¹
- ¶óƾ¾Æ¸Þ¸®Ä«
- Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
- ³²¾ÆÇÁ¸®Ä«°øÈ±¹
- »ç¿ìµð¾Æ¶óºñ¾Æ
- ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
- Äí¿þÀÌÆ®
Á¦9Àå °æÀï ±¸µµ
- Âü¿© ±â¾÷
- ±â¾÷ ½ÃÀå ÇöȲ ºÐ¼®, 2024³â
- °æÀï ½Ã³ª¸®¿À ÅëÂû
- Âü¿© ±â¾÷ °³¿ä
- Thermo Fisher Scientific, Inc.
- Illumina, Inc.
- Danaher
- Merck KGaA
- Abbott Laboratories
- QIAGEN
- Agilent Technologies
- Standard BioTools
- Revvity, Inc.
- Bio-Rad Laboratories
LSH
¿µ¹® ¸ñÂ÷
Lab-on-a-Chip Market Growth and Trends:
The global lab-on-a-chip market size is expected to reach USD 11.45 billion by 2030 and is expected to grow at a CAGR of 9.76% from 2025 to 2030 according to a new report by Grand View Research, Inc. The market is driven by rising investments in healthcare R&D, integration of AI in diagnostics, and government initiatives supporting personalized medicine and decentralized testing.
The lab-on-a-chip market is experiencing significant growth due to advancements in microfluidics technology, which has improved the precision and efficiency of diagnostic processes. In addition, the integration of lab-on-a-chip devices in clinical and research laboratories has streamlined workflows, further reducing the time required for complex analyses. The demand for high-throughput screening in the pharmaceutical and biotechnology industries has also expanded the applications of lab-on-a-chip technology, enabling faster drug discovery and personalized treatment approaches.
Furthermore, the rising adoption of telemedicine and remote patient monitoring has increased the need for portable diagnostic solutions, which has placed lab-on-a-chip as an important component in decentralized healthcare systems. The development of cost-effective manufacturing techniques, including 3D printing and nanofabrication, has enhanced the scalability of lab-on-a-chip production, making these devices more accessible. Moreover, increasing government funding and private investments in healthcare innovation have further accelerated research and commercialization of lab-on-a-chip technologies.
Key market players are adopting various strategies to enhance the effectiveness and reliability of Lab-on-a-Chip technologies by integrating advanced microfluidics, AI-driven analytics, and biomimetic systems. Companies are focusing on improving drug testing accuracy, organ-on-chip models, and point-of-care diagnostics to meet the growing demand for personalized medicine and decentralized healthcare. In September 2024, Emulate, Inc. announced the launch of Chip-R1 Rigid Chip, designed to minimize drug absorption and enhance biological modeling. This innovation addresses the challenge of drug compound loss during in vitro testing, thereby improving the accuracy of pharmacokinetic and toxicological assessments.
Lab-on-a-Chip Market Report Highlights:
- Based on product & service, reagents & consumables dominated the market due to their essential role in diagnostic procedures, ensuring high sensitivity and accuracy. The increasing demand for single-use cartridges and microfluidic reagents has further driven market growth.
- Based on technology, microfluidics technology held the largest revenue share in 2024 due to its ability to enable precise fluid handling at a microscale, improving diagnostic accuracy and efficiency.
- Based on application, clinical diagnostics held the largest revenue share in 2024 due to the increasing need for rapid, cost-effective, and accurate disease detection. The widespread use of Lab-on-a-Chip devices for infectious disease testing, cancer screening, and genetic an a has propelled market growth.
- Based on end use, hospitals, and diagnostic centers held the largest revenue share in 2024 due to their extensive use of lab-on-a-chip technology for diagnostic purposes.
- Based on region, North America dominated the market in 2024 due to the presence of numerous leading pharmaceutical and biotechnology companies, driving the demand for cutting-edge diagnostic and testing solutions.
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation and Scope
- 1.2. Market Definitions
- 1.2.1. Product & Service
- 1.2.2. Technology
- 1.2.3. Application
- 1.2.4. End Use
- 1.3. Information analysis
- 1.4. Market formulation & data visualization
- 1.5. Data validation & publishing
- 1.6. Information Procurement
- 1.7. Information or Data Analysis
- 1.8. Market Formulation & Validation
- 1.9. Market Model
- 1.10. Objectives
Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.3. Competitive Insights
Chapter 3. Lab-on-a-Chip Market Variables, Trends, & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent Market Outlook
- 3.1.2. Related/Ancillary Market Outlook
- 3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
- 3.2.1.1. Increasing Demand for Point Of Care Diagnostics
- 3.2.1.2. Technological Advancements in Microfluidics and Miniaturization
- 3.2.1.3. Increasing Incidence of Chronic Diseases and Infectious Diseases
- 3.2.2. Market Restraint Analysis
- 3.2.2.1. High Development and Manufacturing Costs
- 3.2.2.2. Stringency In Regulatory Approval Processes
- 3.3. Industry Analysis Tools
- 3.3.1. Porter's Five Forces Analysis
- 3.3.2. PESTEL Analysis
- 3.3.3. COVID-19 Impact Analysis
- 3.3.4. AI Integration in Lab-on-a-Chip Market
Chapter 4. Lab-on-a-Chip Market: Product & Service Estimates & Trend Analysis
- 4.1. Product & Service Segment Dashboard
- 4.2. Global Lab-on-a-Chip Market Product & Service Movement Analysis
- 4.3. Global Lab-on-a-Chip Market Size & Trend Analysis, by Product & Service, 2018 to 2030 (USD Million)
- 4.4. Reagents & Consumables
- 4.4.1. Reagents & Consumables Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 4.5. Instruments
- 4.5.1. Instruments Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 4.6. Software & Services
- 4.6.1. Software & Services Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 5. Lab-on-a-Chip Market: Technology Estimates & Trend Analysis
- 5.1. Technology Segment Dashboard
- 5.2. Global Lab-on-a-Chip Market Technology Movement Analysis
- 5.3. Global Lab-on-a-Chip Market Size & Trend Analysis, by Technology, 2018 to 2030 (USD Million)
- 5.4. Microfluidics Technology
- 5.4.1. Microfluidics Technology Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.5. Optical Technology
- 5.5.1. Optical Technology Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.6. Electrochemical Technology
- 5.6.1. Electrochemical Technology Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.7. Others
- 5.7.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 6. Lab-on-a-Chip Market: Application Estimates & Trend Analysis
- 6.1. Application Segment Dashboard
- 6.2. Global Lab-on-a-Chip Market Application Movement Analysis
- 6.3. Global Lab-on-a-Chip Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
- 6.4. Drug Discovery & Development
- 6.4.1. Drug Discovery & Development Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.5. Clinical Diagnostics
- 6.5.1. Clinical Diagnostics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.6. Others
- 6.6.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 7. Lab-on-a-Chip Market: End Use Estimates & Trend Analysis
- 7.1. End Use Segment Dashboard
- 7.2. Global Lab-on-a-Chip Market End Use Movement Analysis
- 7.3. Global Lab-on-a-Chip Market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
- 7.4. Academic & Research Institutes
- 7.4.1. Academic & Research Institutes Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5. Hospitals & Diagnostic Centers
- 7.5.1. Hospitals & Diagnostic Centers Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6. Pharmaceutical & Biotechnological Companies
- 7.6.1. Pharmaceutical & Biotechnological Companies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.7. Others
- 7.7.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 8. Lab-on-a-Chip Market: Regional Estimates & Trend Analysis
- 8.1. Regional Market Share Analysis, 2024 & 2030
- 8.2. Regional Market Dashboard
- 8.3. Market Size & Forecasts and Trend Analysis, 2018 to 2030
- 8.4. North America
- 8.4.1. North America Lab-on-a-Chip Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.4.2. U.S.
- 8.4.2.1. Key Country Dynamics
- 8.4.2.2. Competitive Scenario
- 8.4.2.3. Regulatory Framework
- 8.4.2.4. U.S. Lab-on-a-Chip Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.4.3. Canada
- 8.4.3.1. Key Country Dynamics
- 8.4.3.2. Competitive Scenario
- 8.4.3.3. Regulatory Framework
- 8.4.3.4. Canada Lab-on-a-Chip Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.4.4. Mexico
- 8.4.4.1. Key Country Dynamics
- 8.4.4.2. Competitive Scenario
- 8.4.4.3. Regulatory Framework
- 8.4.4.4. Mexico Lab-on-a-Chip Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.5. Europe
- 8.5.1. Europe Lab-on-a-Chip Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.5.2. UK
- 8.5.2.1. Key Country Dynamics
- 8.5.2.2. Competitive Scenario
- 8.5.2.3. Regulatory Framework
- 8.5.2.4. UK Lab-on-a-Chip Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.5.3. Germany
- 8.5.3.1. Key Country Dynamics
- 8.5.3.2. Competitive Scenario
- 8.5.3.3. Regulatory Framework
- 8.5.3.4. Germany Lab-on-a-Chip Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.5.4. France
- 8.5.4.1. Key Country Dynamics
- 8.5.4.2. Competitive Scenario
- 8.5.4.3. Regulatory Framework
- 8.5.4.4. France Lab-on-a-Chip Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.5.5. Italy
- 8.5.5.1. Key Country Dynamics
- 8.5.5.2. Competitive Scenario
- 8.5.5.3. Regulatory Framework
- 8.5.5.4. Italy Lab-on-a-Chip Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.5.6. Spain
- 8.5.6.1. Key Country Dynamics
- 8.5.6.2. Competitive Scenario
- 8.5.6.3. Regulatory Framework
- 8.5.6.4. Spain Lab-on-a-Chip Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.5.7. Denmark
- 8.5.7.1. Key Country Dynamics
- 8.5.7.2. Competitive Scenario
- 8.5.7.3. Regulatory Framework
- 8.5.7.4. Denmark Lab-on-a-Chip Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.5.8. Sweden
- 8.5.8.1. Key Country Dynamics
- 8.5.8.2. Competitive Scenario
- 8.5.8.3. Regulatory Framework
- 8.5.8.4. Sweden Lab-on-a-Chip Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.5.9. Norway
- 8.5.9.1. Key Country Dynamics
- 8.5.9.2. Competitive Scenario
- 8.5.9.3. Regulatory Framework
- 8.5.9.4. Norway Lab-on-a-Chip Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.6. Asia Pacific
- 8.6.1. Asia Pacific Lab-on-a-Chip Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.6.2. Japan
- 8.6.2.1. Key Country Dynamics
- 8.6.2.2. Competitive Scenario
- 8.6.2.3. Regulatory Framework
- 8.6.2.4. Japan Lab-on-a-Chip Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.6.3. China
- 8.6.3.1. Key Country Dynamics
- 8.6.3.2. Competitive Scenario
- 8.6.3.3. Regulatory Framework
- 8.6.3.4. China Lab-on-a-Chip Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.6.4. India
- 8.6.4.1. Key Country Dynamics
- 8.6.4.2. Competitive Scenario
- 8.6.4.3. Regulatory Framework
- 8.6.4.4. India Lab-on-a-Chip Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.6.5. Australia
- 8.6.5.1. Key Country Dynamics
- 8.6.5.2. Competitive Scenario
- 8.6.5.3. Regulatory Framework
- 8.6.5.4. Australia Lab-on-a-Chip Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.6.6. Thailand
- 8.6.6.1. Key Country Dynamics
- 8.6.6.2. Competitive Scenario
- 8.6.6.3. Regulatory Framework
- 8.6.6.4. Thailand Lab-on-a-Chip Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.6.7. South Korea
- 8.6.7.1. Key Country Dynamics
- 8.6.7.2. Competitive Scenario
- 8.6.7.3. Regulatory Framework
- 8.6.7.4. South Korea Lab-on-a-Chip Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.7. Latin America
- 8.7.1. Latin America Lab-on-a-Chip Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.7.2. Brazil
- 8.7.2.1. Key Country Dynamics
- 8.7.2.2. Competitive Scenario
- 8.7.2.3. Regulatory Framework
- 8.7.2.4. Brazil Lab-on-a-Chip Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.7.3. Argentina
- 8.7.3.1. Key Country Dynamics
- 8.7.3.2. Competitive Scenario
- 8.7.3.3. Regulatory Framework
- 8.7.3.4. Argentina Lab-on-a-Chip Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.8. MEA
- 8.8.1. MEA Lab-on-a-Chip Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.8.2. South Africa
- 8.8.2.1. Key Country Dynamics
- 8.8.2.2. Competitive Scenario
- 8.8.2.3. Regulatory Framework
- 8.8.2.4. South Africa Lab-on-a-Chip Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.8.3. Saudi Arabia
- 8.8.3.1. Key Country Dynamics
- 8.8.3.2. Competitive Scenario
- 8.8.3.3. Regulatory Framework
- 8.8.3.4. Saudi Arabia Lab-on-a-Chip Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.8.4. UAE
- 8.8.4.1. Key Country Dynamics
- 8.8.4.2. Competitive Scenario
- 8.8.4.3. Regulatory Framework
- 8.8.4.4. UAE Lab-on-a-Chip Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.8.5. Kuwait
- 8.8.5.1. Key Country Dynamics
- 8.8.5.2. Competitive Scenario
- 8.8.5.3. Regulatory Framework
- 8.8.5.4. Kuwait Lab-on-a-Chip Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 9. Competitive Landscape
- 9.1. Participant Categorization
- 9.2. Company Market Position Analysis, 2024
- 9.3. Competitive Scenario Insights
- 9.4. Participant's Overview
- 9.4.1. Thermo Fisher Scientific, Inc.
- 9.4.1.1. Participant's Overview
- 9.4.1.2. Financial Performance
- 9.4.1.3. Product/Service Benchmarking
- 9.4.1.4. Strategic Initiatives
- 9.4.2. Illumina, Inc.
- 9.4.2.1. Participant's Overview
- 9.4.2.2. Financial Performance
- 9.4.2.3. Product/Service Benchmarking
- 9.4.2.4. Strategic Initiatives
- 9.4.3. Danaher
- 9.4.3.1. Participant's Overview
- 9.4.3.2. Financial Performance
- 9.4.3.3. Product/Service Benchmarking
- 9.4.3.4. Strategic Initiatives
- 9.4.4. Merck KGaA
- 9.4.4.1. Participant's Overview
- 9.4.4.2. Financial Performance
- 9.4.4.3. Product/Service Benchmarking
- 9.4.4.4. Strategic Initiatives
- 9.4.5. Abbott Laboratories
- 9.4.5.1. Participant's Overview
- 9.4.5.2. Financial Performance
- 9.4.5.3. Product/Service Benchmarking
- 9.4.5.4. Strategic Initiatives
- 9.4.6. QIAGEN
- 9.4.6.1. Participant's Overview
- 9.4.6.2. Financial Performance
- 9.4.6.3. Product/Service Benchmarking
- 9.4.6.4. Strategic Initiatives
- 9.4.7. Agilent Technologies
- 9.4.7.1. Participant's Overview
- 9.4.7.2. Financial Performance
- 9.4.7.3. Product/Service Benchmarking
- 9.4.7.4. Strategic Initiatives
- 9.4.8. Standard BioTools
- 9.4.8.1. Participant's Overview
- 9.4.8.2. Financial Performance
- 9.4.8.3. Product/Service Benchmarking
- 9.4.8.4. Strategic Initiatives
- 9.4.9. Revvity, Inc.
- 9.4.9.1. Participant's Overview
- 9.4.9.2. Financial Performance
- 9.4.9.3. Product/Service Benchmarking
- 9.4.9.4. Strategic Initiatives
- 9.4.10. Bio-Rad Laboratories
- 9.4.10.1. Participant's Overview
- 9.4.10.2. Financial Performance
- 9.4.10.3. Product/Service Benchmarking
- 9.4.10.4. Strategic Initiatives
°ü·ÃÀÚ·á